On the ground of the advanced technology on biochemical, immune, microbial, blood diseases, genetic metabolism and cellular histopathology by Beijing IPE Center for Clinical Laboratory (a wholly owned subsidiary of Lepu), Lepu Gene concentrates on developing the technology of cardiovascular high-throughput gene sequencing, non-invasive prenatal testing (NIPT), and tumor gene sequencing by means of the second generation of gene sequencing platform.In the meantime, Lepu Gene collaborates with Lepu Medical Technology (Beijing) Co., Ltd., who has the Fluorescence Quantitative Polymerase Chain Reaction technology, to actively develop and market the molecular diagnostic reagents related to cardiovascular individualized drug, and thus to establish a closed loop system for R&D, sales and third-party medical testing service based on the molecular diagnostics and high-throughput sequencing.More info
Beijing IPE Center for Clinical Laboratory, founded in 2007, is the first provincial medical independent laboratory approved by Beijing Health Bureau. It specializes in medical testing, medical pathology and scientific research. It is a scientific and technical service oriented company focus on the third-party medical testing.
In 2014, Lepu Medical invested in IPE to co-build a technology-leading third-party testing center by taking the advantages of the projects include cardiovascular disease diagnosis, non-invasive prenatal testing, prenatal and postnatal care, blood disease testing, and remote pathology. With the help of the advanced detection & scientific research platform, excellent product quality, and personalized service, IPE will lead a new era of medical testing market.
We are on a mission to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease. Click on one of the therapeutic category icons below to learn how our revolutionary technology is helping researchers advance the science of precision health. Our digital health solution, Simoa, is changing the way in which the biology of health and disease is studied by giving researchers the ability to closely examine critical biomarkers in numerous therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. We're incredibly passionate about the work we are doing, and whole heartedly believe that we can transform today’s sick care into tomorrow’s precision healthcare through early detection and disease prevention sciences. The future of healthy living is being realized today by uncovering novel biomarkers with the power to transform medicine, allowing for prevention, early diagnosis, and nextgen treatments.More info